According to The Insight Partners – The global Point-of-Care (POC) Molecular Diagnostics market is on a strong upward trajectory, reflecting a fundamental shift in how healthcare systems worldwide approach disease detection and patient management. The market is projected to grow from US$ 3.07 billion in 2025 to US$ 7.96 billion by 2034, registering a compound annual growth rate (CAGR) of 11.17% during the forecast period from 2026 to 2034.
What Is Driving the Market?
The momentum behind this market stems from multiple converging forces. Key dynamics include a heightening global focus on decentralized healthcare, rising demand for rapid and accurate infectious disease testing, and significant advancements in microfluidics and biosensor technologies. The market is also expected to benefit from the growing prevalence of chronic conditions requiring frequent monitoring, the expansion of CLIA-waived testing in retail clinics, and the increasing integration of artificial intelligence for real-time result interpretation in non-laboratory settings.
Among the most notable technology-driven shifts is the move away from traditional PCR machines. The development of techniques like Loop-mediated Isothermal Amplification (LAMP) and Recombinase Polymerase Amplification (RPA) allows for molecular testing without complex thermal cyclers, enabling the creation of lower-cost, portable devices suitable for remote areas.
Get Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00003144
Point-of-Care Molecular Diagnostics Market Segmentation
The POC molecular diagnostics market is broadly segmented by product, technology, application, and end user. Assays and kits hold the largest market share due to the continuous and repetitive demand for consumables and specialized test cartridges required for each diagnostic run. On the technology front, PCR particularly Real-Time PCR (qPCR) accounts for a significant portion of the market due to its high sensitivity and established clinical trust, while isothermal amplification methods continue to gain ground for portable applications.
In terms of applications, infectious diseases represent the primary revenue contributor, driven by testing for respiratory infections, STDs, and tropical diseases. Growth in oncology is also notable, with an increasing focus on rapid liquid biopsies and tumor marker detection at the point of care.
Regional Outlook
North America holds the largest share globally, anchored by a sophisticated healthcare ecosystem and high adoption of innovative technologies in the US and Canada, supported by favorable reimbursement policies and widespread availability of CLIA-waived products. Asia-Pacific is the fastest-growing region, with major modernization programs in China and India driving large-scale adoption. A massive consumer base seeking affordable diagnostics in rural and semi-urban areas, combined with government-supported infectious disease programs, is fueling this expansion.
Europe remains a significant contributor, driven by government-led decentralized testing initiatives to reduce the burden on central hospital laboratories and high demand for rapid antimicrobial resistance (AMR) screening in acute care settings.
Get Full Copy of This Report @ https://www.theinsightpartners.com/buy/TIPRE00003144
Competitive Landscape
Competition is intensifying due to the presence of established leaders such as Abbott, Danaher Corporation (Cepheid), and F. Hoffmann-La Roche Ltd., alongside regional innovators and niche players like Biocartis and Meridian BioScience. Companies are differentiating themselves through multiplexing capabilities, EHR connectivity, and next-generation miniaturization using CRISPR-based and microfluidics technologies.
On the M&A front, in January 2025, bioMérieux announced an agreement to acquire SpinChip Diagnostics ASA, a Norwegian diagnostics company that developed a benchtop immunoassay platform capable of delivering results from a whole blood sample within 10 minutes.
Opportunities Ahead
Significant opportunity exists in embedding AI algorithms into POC devices for automated quality control and predictive analytics, particularly in resource-limited settings. Furthermore, extending molecular POC to bedside cancer biomarker testing and companion diagnostics offers high-margin growth potential beyond infectious disease applications.
The POC molecular diagnostics market is no longer a niche segment — it is fast becoming a cornerstone of modern, decentralized, and patient-centric healthcare delivery worldwide.
Top Trending Reports @
Point of Care Diagnostics Market Growth, Size, Share, Trends, Key Players Analysis, and Forecast till 2031
Colorectal Cancer Diagnostics Market Key Players and Opportunities by 2028
Digital Diagnostics Market Analysis by Size, Share & Growth 2031
About Us –
The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.
Contact Us:
Contact Person: Ankit Mathur
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876
Also Available in : Korean | German | Japanese | French | Chinese | Italian | Spanish
Leave a Reply